These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19508463)

  • 21. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.
    Tourrel C; Bailbé D; Meile MJ; Kergoat M; Portha B
    Diabetes; 2001 Jul; 50(7):1562-70. PubMed ID: 11423477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.
    Tzefos M; Olin JL
    Ann Pharmacother; 2010; 44(7-8):1294-300. PubMed ID: 20530705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats.
    Fan Y; Liu K; Wang Q; Ruan Y; Ye W; Zhang Y
    Exp Eye Res; 2014 Oct; 127():104-16. PubMed ID: 24910901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is exenatide advancing the treatment of type 2 diabetes?
    Doggrell SA
    Expert Opin Pharmacother; 2006 Jan; 7(1):109-12. PubMed ID: 16370928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4.
    Lietzau G; Nyström T; Östenson CG; Darsalia V; Patrone C
    Oncotarget; 2016 Feb; 7(5):5865-76. PubMed ID: 26744321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.
    Davies MJ; Donnelly R; Barnett AH; Jones S; Nicolay C; Kilcoyne A
    Diabetes Obes Metab; 2009 Dec; 11(12):1153-62. PubMed ID: 19930005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis.
    Fan Y; Liu K; Wang Q; Ruan Y; Zhang Y; Ye W
    Mol Vis; 2014; 20():1557-68. PubMed ID: 25489228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
    Nielsen LL; Young AA; Parkes DG
    Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amaranthus caudatus Stimulates Insulin Secretion in Goto-Kakizaki Rats, a Model of Diabetes Mellitus Type 2.
    Zambrana S; Lundqvist LCE; Veliz V; Catrina SB; Gonzales E; Östenson CG
    Nutrients; 2018 Jan; 10(1):. PubMed ID: 29342984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes.
    Kitahara Y; Miura K; Takesue K; Mine T; Wada R; Uchida Y; Ito S; Yagihashi S
    Metabolism; 2002 Nov; 51(11):1452-7. PubMed ID: 12404197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice.
    Li C; Yang M; Hou G; Liu S; Huan Y; Yu D; Sun S; Liu Q; Yan S; Shen Z
    Biol Pharm Bull; 2017 Sep; 40(9):1399-1408. PubMed ID: 28626167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
    Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
    Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.
    Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Detroja J; Patel K; Gandhi T; Patel K; Bahekar R; Jain M
    Pharmacol Rep; 2013; 65(4):927-36. PubMed ID: 24145087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.
    Himeno T; Kamiya H; Naruse K; Harada N; Ozaki N; Seino Y; Shibata T; Kondo M; Kato J; Okawa T; Fukami A; Hamada Y; Inagaki N; Seino Y; Drucker DJ; Oiso Y; Nakamura J
    Diabetes; 2011 Sep; 60(9):2397-406. PubMed ID: 21810596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes.
    Blevins T; Han J; Nicewarner D; Chen S; Oliveira JH; Aronoff S
    Postgrad Med; 2010 May; 122(3):118-28. PubMed ID: 20463421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.
    Ito R; Tsujihata Y; Matsuda-Nagasumi K; Mori I; Negoro N; Takeuchi K
    Br J Pharmacol; 2013 Oct; 170(3):568-80. PubMed ID: 23848179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
    Sahraoui A; Winzell MS; Gorman T; Smith DM; Skrtic S; Hoeyem M; Abadpour S; Johansson L; Korsgren O; Foss A; Scholz H
    PLoS One; 2015; 10(3):e0121204. PubMed ID: 25793295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.